What is the current stock price of Cognition Therapeutics, Inc. (CGTX)?

As of the latest market data, Cognition Therapeutics, Inc. (CGTX) is trading at $0.90. The stock has seen a gain of 5.16% today.

Does Cognition Therapeutics, Inc. (CGTX) pay a dividend?

Based on current data, Cognition Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Cognition Therapeutics, Inc.?

The current market capitalization of Cognition Therapeutics, Inc. (CGTX) is approximately unavailable.

CGTX

Cognition Therapeutics, Inc.·Healthcare

0.90

5.162%(+0.04)

Close Price

0.96

6.566%(+0.06)

After Hours

Last Updated: — ET

52W L: $0.2252W H: $3.83

CGTX NEWS

globenewswire.com

3d ago

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13th at 3:00 p.m. Eastern Time. During her presentation, Ms. Ricciardi will provide an update on progress of the Company's development programs for Alzheimer's disease and dementia with Lewy bodies (DLB).

globenewswire.com

Mar 31

Cognition Therapeutics CEO Issues Letter to Shareholders

Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders, has published CEO Lisa Ricciardi's Letter to Shareholders.

defenseworld.net

Mar 28

Cognition Therapeutics Q4 Earnings Call Highlights

Cognition Therapeutics (NASDAQ: CGTX) used its fourth-quarter and full-year 2025 earnings call to outline a shift in development priorities for its lead candidate, zervimesine (CT-1812), with management saying it will now focus on pursuing a registration path in dementia with Lewy bodies (DLB) psychosis. Company prioritizes DLB psychosis after Phase II data and regulator feedback Chief

seekingalpha.com

Mar 26

Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 26

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 - - Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y.

globenewswire.com

Mar 23

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026 before the market open.

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2021-10-08

Beta

1.40

Websitewww.cogrx.com↗